Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.

Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr

Diabetes care1 Apr 1999Cited by 55 (Europe PMC)

PMID10189536DOI10.2337/diacare.22.4.585PepBankPUB-10189536

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, rhIGF-I added to insulin reduced HbAlc more than intensified insulin alone.
In plain wordsIn type 1 diabetes, added rhIGF-I lowered long-term blood sugar more than intensified insulin alone.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseHbAlc
Study
n = 223
Comparator
Insulin therapy alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
40/40, 80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Measurements
HbAlc decrease
1.2%
rhIGF-I with insulin
HbAlc decrease
0.7%
insulin alone
P value for HbAlc decrease
≤ 0.01 P
rhIGF-I/insulin cotherapy versus intensified insulin therapy alone
Source sentences
Summary
Cotherapy with rhIGF-I/insulin produced a mean decrease in HbAlc of 1.2%, compared with a 0.7% decrease in HbAlc for patients receiving intensified insulin therapy alone (P < or = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953601
02HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, added rhIGF-I reduced daily insulin usage by 11-19%, versus a 7% increase with placebo.
In plain wordsIn type 1 diabetes, added rhIGF-I reduced insulin use, while insulin use increased with placebo.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseDaily insulin usage
Study
n = 223
Comparator
Placebo with standard insulin therapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
40/40, 80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Daily insulin usage decrease
11 to 19%
rhIGF-I/insulin cotherapy
Daily insulin usage increase
7%
placebo group
Source sentences
Summary
Subjects receiving rhIGF-I/insulin cotherapy also decreased their daily insulin usage by 11-19%, compared with a 7% increase in insulin usage reported by the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953602
03HumanRandomized controlled trialSafety outcome
In type 1 diabetes, hypoglycemia incidence was similar with added rhIGF-I and insulin alone.
In plain wordsIn type 1 diabetes, low blood sugar occurred similarly with added rhIGF-I and insulin alone.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHypoglycemia
Study
n = 223
Comparator
Insulin therapy alone
Outcome group
Adverse events · Metabolic and weight
Studied dose
40/40, 80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Moreover, the incidence of hypoglycemia was similar in subjects treated with rhIGF-I/Insulin cotherapy compared with those treated with insulin alone, despite the better glycemic control of the former group.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953603
04HumanRandomized controlled trialSafety outcome
In type 1 diabetes, the 40/40 dose of rhIGF-I was well tolerated.
In plain wordsIn type 1 diabetes, the 40/40 dose of rhIGF-I was well tolerated.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableTolerability at 40/40 dose
Study
n = 56
Outcome group
Adverse events · Metabolic and weight
Studied dose
40/40 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
The 40/40 dose of rhIGF-I was well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953604
05HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, higher rhIGF-I doses did not further improve efficacy.
In plain wordsIn type 1 diabetes, higher rhIGF-I doses did not improve results further than the lower dose.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeEfficacy at higher doses
Study
n: not reported in source
Comparator
40/40 dose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Higher doses of rhIGF-I did not further improve efficacy yet were associated with unacceptable levels of adverse events, including edema, jaw pain, and early worsening of retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953605
06HumanRandomized controlled trialSafety outcome
In type 1 diabetes, higher rhIGF-I doses were associated with unacceptable adverse events including edema.
In plain wordsIn type 1 diabetes, higher rhIGF-I doses were linked to unacceptable side effects including swelling.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableEdema at higher doses
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Higher doses of rhIGF-I did not further improve efficacy yet were associated with unacceptable levels of adverse events, including edema, jaw pain, and early worsening of retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953606
07HumanRandomized controlled trialSafety outcome
In type 1 diabetes, higher rhIGF-I doses were associated with unacceptable adverse events including jaw pain.
In plain wordsIn type 1 diabetes, higher rhIGF-I doses were linked to unacceptable side effects including jaw pain.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableJaw pain at higher doses
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Higher doses of rhIGF-I did not further improve efficacy yet were associated with unacceptable levels of adverse events, including edema, jaw pain, and early worsening of retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953607
08HumanRandomized controlled trialSafety outcome
In type 1 diabetes, higher rhIGF-I doses were associated with early worsening of retinopathy.
In plain wordsIn type 1 diabetes, higher rhIGF-I doses were linked to early worsening of retinal disease.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableEarly worsening of retinopathy
Study
n: not reported in source
Outcome group
Adverse events · Eye
Studied dose
80/40 or 80/60 micrograms/kg A.M/P.M · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Higher doses of rhIGF-I did not further improve efficacy yet were associated with unacceptable levels of adverse events, including edema, jaw pain, and early worsening of retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
while continuing to receive standard insulin therapy.
Report a problemFND-1018953608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.